Terms & Conditions

These Terms and Conditions, together with the Informed Consent provisions herein, constitute a legally binding agreement between you and Medvyy Limited.

By completing the declarations and signing the consent section, you confirm that you have read, understood, and agreed to all provisions. If any part is unclear, contact us before proceeding.

This document is governed by the laws of the Federal Republic of Nigeria. including the Medical and Dental Practitioners Acts (Cap. M8, LFN 2004). the National Health Act 2014, the Nigeria Data Protection Act 2023, and the NAFDAC Act

Medvyy Limited ("Medvyy", "we", "us", or "our") is a digital health platform registered in Nigeria that connects patients with verified medical doctors for online consultations and clinically supervised health programmes, including weight management.

By accessing or using our website, GLP-1 assessment form, or any associated services, you agree to be bound by these Terms and Conditions. If you do not agree, please do not use our services.

All prescribing physicians are registered with the Medical nd Dental Council of Nigeria (MDCN) and hold current annual practicing licenses. MDCN registration numbers are available on request

Contact hello@medvyy.com | www.medvyy.com | Abuja, FCT, Nigeria

To use Medvyy's services you must:

• Be at least 18 years of age
• Be resident in Nigeria where delivery is applicable
• Provide accurate, current, and complete information during registration and assessment
• Have a valid WhatsApp-enabled phone number
• Have access to a refrigerator for medication storage where applicable

Medvyy reserves the right to decline service to anyone who does not meet these requirements or who provides false or misleading information.

By completing our assessment and proceeding to payment, you confirm that:

• All information provided is truthful, accurate, and complete to the best of your knowledge
• You have not withheld any medical history, condition, or medication that may affect your eligibility or safety
• You understand that Medvyy's eligibility determination is based solely on your self-reported information and is not a substitute for a comprehensive in-person medical examination
• You have disclosed all contraindicated conditions including but not limited to: thyroid cancer history, pancreatitis, type 1 diabetes, severe kidney disease, pregnancy, and gallbladder disease

Medvyy and its affiliated doctors accept no liability for adverse outcomes resulting from information that was inaccurate, incomplete, or deliberately withheld by you. In such cases, no refund will be issued and Medvyy reserves the right to terminate your access to our services.

Medvyy is a platform that facilitates access to licensed medical professionals. We are not a hospital, clinic, or medical institution. The doctors on our platform are independent licensed practitioners registered with the Medical and Dental Council of Nigeria (MDCN).

Nothing on this platform constitutes medical advice, diagnosis, or treatment in and of itself. All clinical decisions — including prescribing — are made solely by the licensed doctors on our platform, not by Medvyy.

If you are experiencing a medical emergency, please contact emergency services or visit your nearest hospital immediately. Do not use Medvyy for emergency care.

The Medvyy GLP-1 programme provides access to clinically supervised weight management using semaglutide and tirzepatide-based medications (including Ozempic, Wegovy, and Mounjaro).

GLP-1 Glucagon-like Peptide-1 receptor agonists are injectable medications that mimic a naturally occuring gut hormone to regulate appetite, slow gastric emptying, and improve insulin sensitivity.

Medications in this class include semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®), administered as once-weekly subcutaneous injections.

These medications were originally developed for Type 2 Diabetes Mellitus and have demonstrated significant weight reduction efficacy in multiple large-scale randomised controlled trials.

• GLP-1 medications are prescription-only and will only be dispensed following a doctor consultation and prescription
• You have been made aware of common side effects including nausea, vomiting, diarrhoea, constipation, and injection site reactions
• The medication requires refrigeration at 2–8°C at all times and you have confirmed access to appropriate storage
• The medication is administered via weekly subcutaneous injection and you have confirmed you are able or willing to self-administer or have assistance to do so
• Results vary between individuals and Medvyy makes no guarantee of specific weight loss outcomes
• Medvyy is not responsible for outcomes resulting from non-compliance with the doctor's instructions

Medvyy offers GLP-1 therapy for adults meeting one or more of the following criteria:

• Body Mass Index (BMI) of 30 kg/m² or higher
• BMI of 27 kg/m² or higher with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, Type 2 Diabetes, obstructive sleep apnoea, or non-alcoholic fatty liver disease)
• Type 2 Diabetes Mellitus requiring improved glycaemic control and/or weight reduction

The specific medication, starting dose, and target dose will be determined by your prescribing physician and documented prior to treatment commencement

The National Agency for Food and Drug Administration and Control (NAFDAC) is the Nigerian regulatory body responsible for approving medicines for legal sale in Nigeria. You must be aware of the current position set out below before consenting to treatment.

• Ozempic® (semaglutide up to 2 mg) — not currently registered in the NAFDAC database for legal sale in Nigeria
• Wegovy® (semaglutide 2.4 mg) — not registered with NAFDAC as at the effective date of this document
• Mounjaro® (tirzepatide) — registration status to be confirmed with your physician at time of prescription
• Prescribing GLP-1 medications for weight management in Nigeria therefore constitutes off-label prescribing

Off-label prescribing is the clinical use of a licensed medicine for an indication outside its formal product licence. This is a legally and ethically accepted medical practice in Nigeria and internationally when supported by clinical evidence and accompanied by the patient's fully informed consent. Your prescribing physician accepts personal clinical responsibility for this decision.

By accepting this terms, you acknowledge that you have been fully informed of the regulatory status of these medications in Nigeria and expressly consent to treatment on this basis

The following benefits are supported by published clinical trial evidence. Individual results vary significantly. Medvyy makes no guarantee of any specific outcome. Treatment success also depends on adherence to dietary guidance and lifestyle modification.

• Nausea — the most frequently reported effect, typically during dose escalation and improving with time
• Vomiting
• Diarrhoea or Constipation
• Reduced appetite — an intended mechanism but may feel uncomfortable in the early weeks
• Fatigue, particularly within the first 4–6 weeks of treatment
• Injection site reactions (redness, bruising, itching)

• Gastroparesis (delayed gastric emptying) — persistent nausea, bloating, and early satiety
• Hypoglycaemia — particularly in patients also taking insulin or sulphonylurea medications
• Tachycardia (elevated heart rate) — more common at higher doses
• Hair thinning — typically secondary to rapid weight loss rather than a direct drug effect
• Muscle mass reduction — if weight loss is rapid and dietary protein intake is insufficient

• Severe abdominal pain radiating to the back (possible pancreatitis)
• Yellowing of the skin or eyes, dark urine (possible hepatobiliary disease)
• A lump or swelling in the neck, hoarseness of voice (possible thyroid tumour)
• Severe allergic reaction — facial swelling, throat tightening, difficulty breathing
• Sudden vision changes or deterioration
• Persistent vomiting with inability to retain fluids (risk of dehydration and acute kidney injury

Animal studies have shown an association between GLP-1 receptor agonists and thyroid C-cell tumours. This has not been confirmed in human clinical trials. However, patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) must not use these medications under any circumstances.

GLP-1 receptor agonists have demonstrated renoprotective properties in clinical trials. However, vomiting and reduced fluid intake can precipitate dehydration and acute kidney injury (AKI), particularly in patients with pre-existing chronic kidney disease (CKD). Patients with CKD will be placed on a closer monitoring schedule and dose adjustments may be required in advanced CKD stages.

GLP-1 receptor agonists are not suitable in the following conditions:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Type 1 Diabetes Mellitus
• History of acute or chronic pancreatitis
• Pregnancy and breastfeeding
• Plans to become pregnant within next two months
• Severe gastrointestinal disease (e.g., gastroparesis, inflammatory bowel disease)
• Known allergy or hypersensitivity to GLP-1 receptor agonists or their excipients
• Less than 18 years of age

• Fasting blood glucose and glycated haemoglobin (HbA1c)
• Urea, creatinine, and estimated GFR (eGFR) — kidney function
• Liver function tests (LFTs)
• Full fasting lipid profile
• Thyroid function tests (TSH and free T4)
• Full blood count (FBC)
• Blood pressure and resting heart rate
• Body Weight, height, and BMI calculation
• Urine dipstick and albumin-to-creatinine ratio (ACR) where clinically indicated

NAFDAC has issued multiple public alerts regarding falsified GLP-1 medications circulating through informal markets in Nigeria. Counterfeit products pose serious risks to patient safety

• All medications are sourced exclusively from verified, licensed pharmaceutical importers and distributors
• Batch numbers are documented for every product dispensed and retained for traceability
• Full cold-chain compliance (2–8°C) is maintained throughout storage and delivery
• Written home storage guidance is provided to every patient with their prescription

• Do not purchase GLP-1 medications from any source other than Medvyy or a licensed pharmacy with a valid prescription from a registered physician
• Do not purchase from social media vendors, WhatsApp groups, online marketplaces, or informal markets
• Unopened pens must be stored in the refrigerator at 2–8°C; once in use, semaglutide pens may be stored at room temperature below 30°C for up to 56 days
• Inspect each pen for discolouration, particles, or physical damage before use — discard and contact Medvyy if any abnormality is noted

By enrolling in this programme, you agree to the following obligations:

• Attend all scheduled follow-up appointments as set out in Section 9, whether in-clinic or via approved teleconsultation
• Adhere to dietary guidance, including adequate protein intake (minimum 1.2 g per kilogram of body weight per day) to protect lean muscle mass
• Engage in regular physical activity — a minimum of 150 minutes of moderate-intensity exercise per week
• Disclose all new medications prescribed by any other physician to Medvyy before commencing them
• Report any new, worsening, or concerning symptoms promptly; seek emergency care immediately for warning signs listed in Section 7.3
• Do not share your medication or WhatsApp contact with anyone else under any circumstances
• Inform Medvyy without delay if you become pregnant or are planning to conceive
• Maintain adequate daily hydration — a minimum of 2 litres of water per day

• Programme fees cover the initial medical consultation, clinical assessment, prescription, and follow-up consultations per the monitoring schedule in Section 9
• Medication costs are separate from programme fees and will be communicated at the time of prescription before any medication is dispensed
• All fees are non-refundable once a consultation has been completed and a prescription issued
• Medvyy makes no guarantee of specific clinical outcomes; fees are for clinical services rendered, not results achieved
• Fees may be amended with a minimum of 30 days' written notice; currently enrolled patients will receive advance notification

All payments are processed securely via our Gateway Partners (Monnify or Paystack). By completing payment you agree to the following:

• Payment is collected prior to medication dispatch and doctor WhatsApp consultation
• Prices displayed are in Nigerian Naira (₦) and include medication costs
• Refunds will only be considered if medication has not yet been dispatched and a written request is made within 24 hours of payment
• No refund will be issued where a doctor has already been assigned and has initiated contact
• No refund will be issued where inaccurate information was provided during assessment
• Medvyy reserves the right to cancel and refund any order at its discretion

• The right to receive complete, clear information about your diagnosis, treatment, alternatives, and risks in plain language
• The right to refuse or withdraw from treatment at any time without prejudice
• The right to seek a second opinion from an independent clinician at any stage
• The right to access your complete medical records held by Medvyy upon written request
• The right to know the name, qualifications, and MDCN registration number of your treating physician
• The right to make a formal complaint without fear of retribution (see Section 16)
• The right to be treated with dignity, respect, and without discrimination

• Inadequate response — less than 5% total body weight loss after 12–16 weeks at optimal dose with good adherence
• Development of a contraindication after treatment commences (e.g. confirmed pregnancy, new diagnosis of MTC or MEN2)
• A serious adverse event attributable to treatment
• Patient request — at any time and without the need to provide a reason
• Non-attendance at mandatory monitoring reviews on more than one occasion
• Clinical decision by the treating physician in the patient's best interest

Abrupt discontinuation typically results in return of appetite to pre-treatment levels and progressive weight regain. Medvyy will offer all discontinuing patients a supervised tapering plan and lifestyle support. Please notify your Medvyy physician before stopping your medication.

1. Raise your concern directly with your treating Medvyy physician in the first instance
2. If unresolved, submit a formal written complaint to: complaints@medvyy.com
3. Complaints will be acknowledged within 3 working days and investigated within 21 working days
4. If unsatisfied after Medvyy's internal process, escalate to the Medical and Dental Council of Nigeria (MDCN)

Medvyy will arrange delivery of medication to the address provided during checkout. You are responsible for ensuring the address and landmark information provided is accurate. Medvyy is not liable for failed or delayed deliveries resulting from inaccurate address information.

Medication must be received and refrigerated promptly upon delivery. Medvyy accepts no liability for medication that is compromised due to delayed receipt or improper storage by the recipient.

All doctors on the Medvyy platform are verified, MDCN-registered practitioners. Medvyy takes reasonable steps to verify credentials but does not guarantee any specific clinical outcome. Any concerns about a doctor's conduct should be reported to us immediately at hello@medvyy.com.

The WhatsApp number provided after payment is for medical consultation only and should be used respectfully during reasonable hours. Misuse or harassment of doctors may result in immediate termination of your access to the platform.

To the fullest extent permitted by Nigerian law, Medvyy's total liability to you for any claim arising from or related to these Terms or your use of our services shall not exceed the amount you paid for the specific service giving rise to the claim.

Medvyy is not liable for any indirect, incidental, or consequential damages including but not limited to adverse medical reactions resulting from undisclosed conditions, loss of data, or service interruptions.

Medvyy reserves the right to suspend or terminate your access to our services at any time, with or without notice, if we reasonably believe you have violated these Terms, provided false information, or engaged in conduct harmful to our doctors, staff, or other users.

These Terms are governed by and construed in accordance with the laws of the Federal Republic of Nigeria. Any dispute arising from these Terms shall be subject to the exclusive jurisdiction of the Nigerian courts.

If you have any questions about these Terms and Conditions, please contact us at:

• Email: hello@medvyy.com
• Website: medvyy.com

Medvyy Limited · Nigeria